Medicaid lost $1 billion in savings to illegal medical cannabis

Cost efficiency is a major concern for any healthcare provider, always searching for a more affordable, effective method of treatment. Medicaid has not been able to cash in the savings after reported having lost out on $1 billion in saving on prescriptions if cannabis were legalized.

A recent article by Forbes examined a recent Health Affairs study. Between 2007 and 2014, Medicare Part D enrollees were able to replace expensive prescription drugs with medical cannabis. The switch from pill to leaf was estimated at an average saving of $19.83 million per state per year.

“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” wrote lead authors Ashley C. Bradford and W. David Bradford. “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.”

Read the full story by clicking the link below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.